Free Republic

Texas scientists rolled out a new COVID-19 vaccine, saying it’s patent-free and can be produced by any manufacturer in any country. The vaccine, called Corbevax, was developed by the Texas Children’s Hospital and Baylor College of Medicine. It has successfully passed human trials as safe and effective. The new treatment is based off protein-based technology that has been used in other vaccines for decades and it does not use MRNA. India has already authorized production of 100 million doses per month of the new vaccine. Meanwhile, Texas scientists say not-for-profit vaccines will help defeat COVID-19 quicker.

A vaccine authorized in December for use in India may help solve one of the most vexing problems in global public health: How to supply lower-income countries with a COVID-19 vaccine that is safe, effective and affordable.The vaccine is called CORBEVAX. It uses old but proven vaccine technology and can be manufactured far more easily than most, if not all, of the COVID-19 vaccines in use today."CORBEVAX is a game changer," says Dr. Keith Martin, executive director of the Consortium of Universities for Global Health in Washington, D.C. "It's going to enable countries around the world, particularly low-income countries, to...

A new COVID-19 vaccine, developed by researchers from the Texas Children’s Hospital and Baylor College of Medicine, is being offered patent-free to vaccine manufacturers across the world. Human trials have shown the vaccine to be safe and effective, with India already authorizing its use as production ramps up to over 100 million doses per month. The vaccine has been named Corbevax and it is based on a traditional protein-based technology that has been safely used for decades. Like other COVID-19 vaccines, Corbevax focuses on the coronavirus spike protein, but instead of using mRNA to direct our cells to produce those...

Houston: The Texas Children's Hospital (TCH) and Baylor College of Medicine (BCM) announced on Tuesday that Corbevax, a protein subunit Covid vaccine, has received approval from the Drugs Controller General of India (DCGI) to launch it in India. The initial construct and production process of the vaccine antigen was developed at TCH's Centre for Vaccine Development, led by co-directors Maria Elena Bottazzi and Peter Hotez.. ...TCH said the vaccine has been through phase three clinical trials with more than 3,000 subjects and was found to be safe and well-tolerated. The trials suggested a better immune response to the Ancestral-Wuhan strain...